Upstream Bio, Inc.

NASDAQ:UPB

Biotechnology

Healthcare
$2.08 +1.63%

+$0.10 today

Market cap
$114.01M
Beta
1.11
P/E (TTM)
-2.2
EPS (TTM)
-$2.89
52W Low $5.85High $33.68

Volume 1.24M

Average 0.66M

UPB Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Upstream Bio, Inc.NASDAQ: UPB

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income grows, but more slowly than its trailing trend

Q1 FY2026 net income of $40.59M (cash outflow) rose 48.8% year over year, behind the +98.0% change in trailing-twelve-month net income. Sequentially, it fell 4.4% from the prior quarter. Over 3 fiscal years it compounded at +81.8% a year.

Context

  • Net income amounted to 5026.0% of revenue in FY2025, up 2376.0 pp from a year earlier.
  • Net income grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 5 analysts of -$167.46M (+16.7%) for the fiscal year ending Dec 2026, a slowdown from the +128.4% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$40.59M-4.4% QoQ
Last fiscal yearDec 2025
-$143.44M+128.4% YoY
LTMMar 2026
-$156.76M+98.0% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+48.8%+2.0%-46.8 pp
1 year+128.4%+16.7%-111.6 pp
3-year CAGR+81.8%+0.7%-81.1 pp
5-year CAGR+0.6%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(143.44M) USD
Year-over-year change
-128.4%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How UPB compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +98.0% is the 2nd highest of 10, against a peer median of +9.3%.
  • Net income amounts to 4719.0% of revenue for UPB, versus a peer median of 273.6%.
UPB Competitors
Net Income for UPB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NTLAIntellia Therapeutics, Inc.LTM Mar 2026$500.92M USD-4.8%+3.1%757.9%
ZBIOZenas BioPharma, Inc.LTM Mar 2026$425.15M USD+161.2%+46.8%—
RLAYRelay Therapeutics, Inc.LTM Jun 2026$286.04M USD-8.2%-1.6%2763.6%
SYRESpyre Therapeutics, Inc.LTM Sep 2026$263.86M USD+77.1%+22.8%291.6%
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 2026$243.25M USD-26.6%+24.1%112.0%
WVEWave Life Sciences Ltd.LTM Mar 2026$183.59M USD+63.4%+8.1%255.7%
PHVSPharvaris N.V.LTM Sep 2026€179.96M EUR+11.0%+31.9%—
AMLXAmylyx Pharmaceuticals, Inc.LTM Sep 2026$163.2M USD+9.3%-10.0%—
UPBUpstream Bio, Inc.LTM Mar 2026$156.76M USD+98.0%+81.8%4719.0%
NVAXNovavax, Inc.LTM Mar 2026$87.84M USD-118.3%—14.7%
Peer median (excluding UPB) —+9.3%+15.4%273.6%

Competitors are the stored peer set for UPB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(23.87M)(20.54M)(62.81M)(143.44M)
Depreciation & Amortization7K60K89K(1.31M)
Deferred Income Tax0000
Stock-Based Compensation1.28M3.43M6M10.33M
Change in Working Capital3.41M(4.31M)1.87M589K
Accounts Receivables(412K)314K(515K)(55K)
Inventory0000
Accounts Payables462K1.28M2.02M(1.28M)
Other Working Capital3.36M(5.9M)371K1.93M
Other Non-Cash Items149K(16.57M)(4.33M)561K
Operating Cash Flow(19.02M)(37.93M)(59.17M)(133.28M)
Capital Expenditures(82K)(144K)(511K)(165K)
Acquisitions (Net)0000
Purchases of Investments0(128.99M)(290.61M)(385.88M)
Sales of Investments046.29M231.64M292.56M
Other Investing Activities0000
Investing Cash Flow(82K)(82.84M)(59.49M)(93.48M)
Debt Repayment0000
Common Stock Issued9.96M129.55M272.72M2.44M
Common Stock Repurchased0000
Dividends Paid0000
Other Financing Activities(37K)118K(3.74M)0
Financing Cash Flow9.96M129.55M418.91M2.44M
Effect of Forex Changes0000
Net Change in Cash(9.14M)8.78M300.25M(224.31M)
Free Cash Flow(19.1M)(38.07M)(59.68M)(133.28M)

Upstream Bio, Inc.

NASDAQ:UPB

Intrinsic Alpha fair value

Locked

Current Price

$2.08

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.